Cargando…

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

PURPOSE: Resistance to endocrine therapy poses a major clinical challenge for patients with hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC). We present the preplanned 24-month final overall survival (OS) results, alongside up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamilton, Erika, Cortes, Javier, Ozyilkan, Ozgur, Chen, Shin-Cheh, Petrakova, Katarina, Manikhas, Aleksey, Jerusalem, Guy, Hegg, Roberto, Huober, Jens, Zhang, Wei, Chen, Yanyun, Martin, Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338008/ https://www.ncbi.nlm.nih.gov/pubmed/35829935 http://dx.doi.org/10.1007/s10549-022-06662-9

Ejemplares similares

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
por: Toi, Masakazu, et al.
Publicado: (2021)

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
por: Zhang, Qing Yuan, et al.
Publicado: (2020)

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
por: Goetz, Matthew P., et al.
Publicado: (2020)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
por: Toi, Masakazu, et al.
Publicado: (2022)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
por: Johnston, Stephen, et al.
Publicado: (2021)

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
por: Goetz, Matthew P., et al.
Publicado: (2021)

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2
por: Toi, Masakazu, et al.
Publicado: (2022)

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
por: Rugo, Hope S., et al.
Publicado: (2022)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
por: Martin, Miguel, et al.
Publicado: (2022)

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
por: Lim, Elgene, et al.
Publicado: (2022)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
por: Wei, Qiran, et al.
Publicado: (2023)

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
por: Johnston, Stephen, et al.
Publicado: (2019)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
por: Sledge, George W., et al.
Publicado: (2019)

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels
por: Masuda, Norikazu, et al.
Publicado: (2022)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
por: Bachelot, Thomas, et al.
Publicado: (2013)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
por: Davie, Alison, et al.
Publicado: (2023)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
por: Inoue, Kenichi, et al.
Publicado: (2021)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

MonarchBase: the monarch butterfly genome database
por: Zhan, Shuai, et al.
Publicado: (2013)

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
por: Gjerde, Jennifer, et al.
Publicado: (2012)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer
por: Hao, Chunfang, et al.
Publicado: (2022)

Monarchs and Medicine
Publicado: (1899)

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
por: Nozawa, K., et al.
Publicado: (2023)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
por: Lu, Yen-Shen, et al.
Publicado: (2022)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Abemaciclib for breast cancer
Publicado: (2020)

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
por: Sanchez-Spitman, A. B., et al.
Publicado: (2018)

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
por: Bychkovsky, Brittany, et al.
Publicado: (2022)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_shmsa8qkpid5j9ohjardt56bq0